Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Stephens & Co. Maintains Equal-Weight on Amedisys, Lowers Price Target to $106

Stephens & Co. analyst Scott Fidel maintains Amedisys (NASDAQ:AMED) with a Equal-Weight and lowers the price target from $122 to $106.
byBenzinga Newsdesk
November 11, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Stephens & Co. analyst Scott Fidel maintains Amedisys (NASDAQ:AMED) with a Equal-Weight and lowers the price target from $122 to $106.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0